Hims, Novo Nordisk
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
CVS Caremark and Express Scripts, along with GoodRx and others, are accused of working together to suppress reimbursements to independent pharmacies in at least three class-action lawsuits. Also, Hims ...
Hims & Hers anticipates selling a generic version of NVO's liraglutide, threatening sales as soon as next year. Intense ...
Hims & Hers shares had previously surged after announcing they would sell compounded versions of GLP-1 injections. What Happened: A report from the FDA on Wednesday shows that all doses of Novo ...
Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.
Hims & Hers Health, Inc. (NYSE:HIMS) has been under pressure this week, with shares declining over 10%, following Eli Lilly's (NYSE:LLY) recent earnings report. Eli Lilly reported a significant ...
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback